The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof.

An antithrombogenic material includes a coating material containing: a cationic polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and a base material whose surface is coated with the coating material; wherein the cationic polymer is covalently bound to the base material; the anionic compound containing a sulfur atom and having anticoagulant activity is immobilized on the surface of the base material by ionic bonding to the cationic polymer; and the average thickness of the coating material is 15 to 400 nm.

An antithrombogenic material includes a coating material containing: a cationic polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and a base material whose surface is coated with the coating material; wherein the cationic polymer is covalently bound to the base material; the anionic compound containing a sulfur atom and having anticoagulant activity is immobilized on the surface of the base material by ionic bonding to the cationic polymer; and the average thickness of the coating material is 15 to 400 nm.

The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.

The present invention is directed to materials compatible with blood, implantable devices comprising said material, methods of preparation of such material and medical devices coated therewith and uses thereof for anti-thrombotic and/or cell-proliferating aspects.

The present invention is directed to materials compatible with blood, implantable devices comprising said material, methods of preparation of such material and medical devices coated therewith and uses thereof for anti-thrombotic and/or cell-proliferating aspects.

A thrombo-resistant catheter includes a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an intraluminal surface and an extraluminal surface, and the hydrogel coating is disposed on the intraluminal surface and/or the extraluminal surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt. % to about 1 wt. % tissue plasminogen activator. The hydrogel coating may be made of a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide-based hydrogels. Presently preferred natural hydrogels include hyaluronic acid-based hydrogels. The hydrogel coating reacts in the presence of a physiological fluid to absorb water and elute the thrombolytic agent. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluid include interstitial fluid and blood.

A thrombo-resistant catheter includes a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an intraluminal surface and an extraluminal surface, and the hydrogel coating is disposed on the intraluminal surface and/or the extraluminal surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt. % to about 1 wt. % tissue plasminogen activator. The hydrogel coating may be made of a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide-based hydrogels. Presently preferred natural hydrogels include hyaluronic acid-based hydrogels. The hydrogel coating reacts in the presence of a physiological fluid to absorb water and elute the thrombolytic agent. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluid include interstitial fluid and blood.